At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for pulmonary diseases and rare blood disorders.
The clinical trials listed below are Acceleron or partner-sponsored trials, some of which are actively recruiting patients. Each trial in the list contains a link to clinicaltrials.gov, where you will find a full description and contact information.
Clinical Trial Transparency: Acceleron is committed to public health and scientific exchange. As a part of this commitment, we make our clinical trial information accessible so that patients, healthcare providers, and the general public are included in the conversation. Click here to learn more about Acceleron’s Policy on Clinical Trial Transparency.
|Sotatercept||STELLAR Phase III||Pulmonary Arterial Hypertension|
|Sotatercept||PULSAR Phase II||Pulmonary Arterial Hypertension|
|Sotatercept||SPECTRA Phase II||Pulmonary Arterial Hypertension|
|Luspatercept||COMMANDS Phase III*||Low or Intermediate Risk MDS|
|Luspatercept||BEYOND Phase II*||Beta-Thalassemia|
|Acceleron trials listed as recruiting or active on www.clinicaltrials.gov|
* Bristol Myers Squibb-sponsored